About Atea Pharmaceuticals
Atea Pharmaceuticals is a company based in Boston (United States) founded in 2014 by Jean Pierre Sommadossi. It operates as a Professional Services. Atea Pharmaceuticals has raised $293.43 million across 6 funding rounds from investors including Bain Capital, RA Capital and Perceptive Advisors. The company has 56 employees as of December 31, 2024. Atea Pharmaceuticals offers products and services including Bemnifosbuvir + Ruzasvir and AT-527. Atea Pharmaceuticals operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Boston, United States
- Employees 56 as on 31 Dec, 2024
- Founders Jean Pierre Sommadossi
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Atea Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$168.38 M (USD)-23.85as on Dec 31, 2024
-
EBITDA
-$192.53 M (USD)-17.58as on Dec 31, 2024
-
Total Equity Funding
$293.43 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Bain Capital
& 11 more
-
Employee Count
56
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Atea Pharmaceuticals
Atea Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AVIR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Atea Pharmaceuticals
Atea Pharmaceuticals offers a comprehensive portfolio of products and services, including Bemnifosbuvir + Ruzasvir and AT-527.
Combination therapy developed for treating Hepatitis C virus.
Therapy developed for treatment of COVID-19 patients.
People of Atea Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Atea Pharmaceuticals
Atea Pharmaceuticals has successfully raised a total of $293.43M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Atea Pharmaceuticals
Atea Pharmaceuticals has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Bain Capital, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Debt and equity investments are pursued across multiple sectors.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked |
Investor details for Atea Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atea Pharmaceuticals
Investment portfolio details for Atea Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atea Pharmaceuticals
Detailed financials for Atea Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atea Pharmaceuticals Comparisons
Peer comparison for Atea Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atea Pharmaceuticals
Atea Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Atea Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atea Pharmaceuticals
Complete news archive for Atea Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atea Pharmaceuticals
Atea Pharmaceuticals was founded in 2014.
Atea Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jean Pierre Sommadossi is the current CEO of Atea Pharmaceuticals. They have also founded this company.
Atea Pharmaceuticals is a funded company, having raised a total of $293.43M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Atea Pharmaceuticals is 56.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapies for serious viral diseases. The company is primarily engaged in advancing treatments for Hepatitis C virus (HCV) through its regimen of bemnifosbuvir and ruzasvir, which is in a global Phase 3 development program. Additionally, innovative therapies are being developed to address unmet medical needs in the antiviral sector, including collaborations for COVID-19 treatments. A deep understanding of antiviral drug development, medicinal chemistry, and virology is leveraged to create novel product candidates targeting single-stranded RNA viruses.
Atea Pharmaceuticals's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Atea Pharmaceuticals offers Bemnifosbuvir + Ruzasvir and AT-527.
Yes, Atea Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AVIR.
Atea Pharmaceuticals has 12 investors. Key investors include Bain Capital, RA Capital, Perceptive Advisors, GSA Capital Partners, and Rock Springs Capital.
The ticker symbol of Atea Pharmaceuticals is AVIR on NASDAQ.